<DOC>
	<DOCNO>NCT01137383</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy locally produce 40KD pegylated interferon alpha-2a ( Pegaferon ) patient hepatitis C. 100 patient treat use standard guideline hepatitis C. Response treatment side effect record .</brief_summary>
	<brief_title>Pegaferon Ribavirin Hepatitis C</brief_title>
	<detailed_description>The product locally produce need evaluate term efficacy safety .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Chronic hepatitis C Age 15 65 previous treatment chronic hepatitis C coinfection human immunodeficiency virus hepatitis B virus major thalassemia hemophilia active drug user treat major depression psychosis decompensated cirrhosis serum creatinine &gt; 1.5 mg/dL solid organ transplant untreated thyroid disease uncontrolled diabetes mellitus uncontrolled autoimmune disease advance cardiac pulmonary disease . plan become pregnant next 1.5 year patient inadequate contraception consenting study</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Hepatitis C</keyword>
</DOC>